These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25562773)

  • 21. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
    Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations between statin adherence level, health care costs, and utilization.
    Zhao Y; Zabriski S; Bertram C
    J Manag Care Spec Pharm; 2014 Jul; 20(7):703-13. PubMed ID: 24967523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
    Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
    Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost and Consequences of Nonadherence With Oral Bisphosphonate Therapy: Findings From a Real-World Data Analysis.
    Sharman Moser S; Yu J; Goldshtein I; Ish-Shalom S; Rouach V; Shalev V; Modi A; Chodick G
    Ann Pharmacother; 2016 Apr; 50(4):262-9. PubMed ID: 26783359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
    Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
    J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
    Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.
    Majumdar SR; Johnson JA; Lier DA; Russell AS; Hanley DA; Blitz S; Steiner IP; Maksymowych WP; Morrish DW; Holroyd BR; Rowe BH
    Osteoporos Int; 2007 Mar; 18(3):261-70. PubMed ID: 17086470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model.
    Patrick AR; Schousboe JT; Losina E; Solomon DH
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2762-70. PubMed ID: 21733991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
    Brookhart MA; Avorn J; Katz JN; Finkelstein JS; Arnold M; Polinski JM; Patrick AR; Mogun H; Solmon DH
    Am J Med; 2007 Mar; 120(3):251-6. PubMed ID: 17349448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.